A Canadian government decision to override the patent for the anti-anthrax drug Cipro and buy a generic version brought threats Friday of possible legal action from the antibiotic's maker, Bayer AG. In the United States, officials have said they have the right to override a similar Bayer patent on Cipro, but Bayer has promised to triple production of the drug to meet U.S. government needs.
October 19, 2001 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
The New Jersey State Commission of Investigation (SCI) is seeking an experienced and visionary leader to serve as its next Executive Directo...
We are a boutique firm specializing the area of real estate law and handling both litigation and transactional matters. We are seeking an as...
Rabb, Hamill, P.A, located in Woodbridge, NJ, seeks an experienced NJ licensed Personal Injury Trial attorney. The successful candidate wi...